Boston Scientific’s 4Q17 Sales Exceeded Analysts’ Estimates



BSX’s 4Q17 earnings results

On February 1, 2018, Boston Scientific (BSX) released its 4Q17 and 2017 earnings results. The company’s 4Q17 revenue came in at $2.41 billion, exceeding Wall Street’s estimate of ~$2.38 billion.

On a YoY (year-over-year) basis, the company reported sales growth of ~9.9% in 4Q17. For the whole of 2017, Boston Scientific reported sales growth of 7.9% on total sales of $9.1 billion. On February 1, BSX stock registered a fall of ~1.2%.

Peers Baxter International (BAX), Thermo Fisher Scientific (TMO), and Abbott Laboratories (ABT) registered sales growths of 4.9%, 22.1%, and 42.3%, respectively, in their recently reported quarters.

Article continues below advertisement

4Q17 sales results

Boston Scientific reported sales of ~$2.41 billion in 4Q17. These results exceeded the company’s guidance range of 5%–6% operational sales growth, coming in at ~8% excluding currency impacts. Strong performances across its business segments and geographies drove the company’s sales growth. Its 4Q17 sales saw an impact of $37 million due to currency tailwinds.

Boston Scientific’s 4Q17 organic sales growth came in at ~7%. Its acquisitions of Symetis and Endochoice had an impact of ~1.3% on its 4Q17 sales.

Sales by geography

Boston Scientific reported balanced global growth in 4Q17. In the United States, the company witnessed sales growth of ~8% on an organic basis. The EMEA (Europe, the Middle East, and Africa) region also registered a rise of ~8% in its sales in 4Q17. In emerging markets, Boston Scientific’s sales growth came in at ~13% led by strong YoY sales growth of ~19% in China.

Next, we’ll take a look at BSX’s MedSurg business’s recent performance and its 2018 growth drivers.


More From Market Realist